Cargando…

Addressing Cardiovascular Risk of Prostate Cancer Hormonal Therapy

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Ryan, Charles J., Morgans, Alicia K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351975/ https://www.ncbi.nlm.nih.gov/pubmed/34396211 http://dx.doi.org/10.1016/j.jaccao.2020.02.002

Ejemplares similares

Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams
por: Shore, Neal D., et al.
Publicado: (2022)

A review of prostate cancer treatment impact on the CNS and cognitive function
por: Ryan, Charles, et al.
Publicado: (2019)

Duration of Androgen Deprivation Therapy and Cardiovascular Fitness: Delivering the Right Patient the Right Therapy at the Right Time
por: Narayan, Vivek, et al.
Publicado: (2020)

How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope
por: Narayan, Vivek, et al.
Publicado: (2021)

Cardiovascular effects of hormone therapy for prostate cancer
por: Lester, Jason F, et al.
Publicado: (2015)

Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK
por: Gonzalez, Juan Marcos, et al.
Publicado: (2023)

Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
por: Wefel, Jeffrey S., et al.
Publicado: (2022)

Cardiovascular risk during hormonal treatment in patients with prostate cancer
por: Van Poppel, Hein, et al.
Publicado: (2011)

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer
por: Beer, Tomasz M., et al.
Publicado: (2022)

Addressing the “Common Soil” of Risk Factors for Cardiovascular Disease and Cancer
por: Hibler, Elizabeth A., et al.
Publicado: (2021)

Patient expectations of benefit from systemic treatments for metastatic prostate cancer
por: Oswald, Laura B., et al.
Publicado: (2019)

Treatment Decision-Making in Metastatic Prostate Cancer: Perceptions of Locus of Control Among Patient, Caregiver, and Physician Triads
por: Schumacher, Frank A, et al.
Publicado: (2022)

Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
por: Sonnenburg, Daniel, et al.
Publicado: (2018)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Optimal assessment of quality of life for patients with prostate cancer
por: Briggs, Logan G, et al.
Publicado: (2022)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study
por: Oswald, Laura B, et al.
Publicado: (2020)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Past, Current, and Future of Immunotherapies for Prostate Cancer
por: Boettcher, Adeline N., et al.
Publicado: (2019)

Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy
por: Chang, Wei-Ting, et al.
Publicado: (2022)

Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins
por: Berglind, Ingegärd Anveden, et al.
Publicado: (2015)

Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
por: Leaning, Darren, et al.
Publicado: (2023)

RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
por: Morgans, Alicia K., et al.
Publicado: (2011)

Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer
por: Ma, Bing-Lei, et al.
Publicado: (2019)

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate
por: Saad, Fred
Publicado: (2022)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer
por: Teoh, Jeremy YC, et al.
Publicado: (2015)

Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis
por: Liu, Wen, et al.
Publicado: (2021)

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD
por: de Wit, Ronald, et al.
Publicado: (2022)

Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer
por: Hou, Cheng-Pang, et al.
Publicado: (2014)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy
por: Buxton, Alison K., et al.
Publicado: (2022)

Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer
por: Baron, D., et al.
Publicado: (2023)

Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2023)

The side effects of hormonal therapy at the patients with prostate cancer
por: Ziółkowska, Ewa, et al.
Publicado: (2013)

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer
por: Miura, Yuji, et al.
Publicado: (2019)

Prostate Cancer and Cardiovascular Risk Factors
por: Lin, Cha-An, et al.
Publicado: (2023)

Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)

Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy
por: Kaboteh, Reza, et al.
Publicado: (2013)

Duodenal microbiome changes in postmenopausal women: effects of hormone therapy and implications for cardiovascular risk
por: Leite, Gabriela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t3v10q9525lilirl2t6k9eb9q1